Molecular Imaging of Inflammation - current and emerging technologies for diagnosis and treatment

MacRitchie, N., Frleta-Gilchrist, M., Sugiyama, A., Lawton, T., McInnes, I. B. and Maffia, P. (2020) Molecular Imaging of Inflammation - current and emerging technologies for diagnosis and treatment. Pharmacology and Therapeutics, 211, 107550. (doi: 10.1016/j.pharmthera.2020.107550)

[img]
Preview
Text
214145.pdf - Published Version
Available under License Creative Commons Attribution.

2MB

Abstract

Inflammation is a key factor in multiple diseases including primary immune-mediated inflammatory diseases e.g. rheumatoid arthritis but also, less obviously, in many other common conditions, e.g. cardiovascular disease and diabetes. Together, chronic inflammatory diseases contribute to the majority of global morbidity and mortality. However, our understanding of the underlying processes by which the immune response is activated and sustained is limited by a lack of cellular and molecular information obtained in situ. Molecular imaging is the visualization, detection and quantification of molecules in the body. The ability to reveal information on inflammatory biomarkers, pathways and cells can improve disease diagnosis, guide and monitor therapeutic intervention and identify new targets for research. The optimum molecular imaging modality will possess high sensitivity and high resolution and be capable of non-invasive quantitative imaging of multiple disease biomarkers while maintaining an acceptable safety profile. The mainstays of current clinical imaging are computed tomography (CT), magnetic resonance imaging (MRI), ultrasound (US) and nuclear imaging such as positron emission tomography (PET). However, none of these have yet progressed to routine clinical use in the molecular imaging of inflammation, therefore new approaches are required to meet this goal. This review sets out the respective merits and limitations of both established and emerging imaging modalities as clinically useful molecular imaging tools in addition to potential theranostic applications.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McInnes, Professor Iain and Maffia, Dr Pasquale and Frleta, Dr Marina and MacRitchie, Dr Neil
Authors: MacRitchie, N., Frleta-Gilchrist, M., Sugiyama, A., Lawton, T., McInnes, I. B., and Maffia, P.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Pharmacology and Therapeutics
Publisher:Elsevier
ISSN:0163-7258
ISSN (Online):1879-016X
Published Online:20 April 2020
Copyright Holders:Copyright © 2020 The Authors
First Published:First published in Pharmacology and Therapeutics 211: 107550
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
190580Defining innate and adaptive immune functions of plasmacytoid dendritic cells in atherosclerosis.Pasquale MaffiaBritish Heart Foundation (BHF)PG/12/81/29897III - Immunology
190814BHF centre of excellenceRhian TouyzBritish Heart Foundation (BHF)RE/13/5/30177Institute of Cardiovascular & Medical Sciences
190739In Situ Nanoparticle Assemblies for Healthcare Diagnostics and Therapy. Reference: 130479Pasquale MaffiaEngineering and Physical Sciences Research Council (EPSRC)EP/L014165/1III - Immunology
171799NanoMATePasquale MaffiaEuropean Commission (EC)661369III - Immunology